Standard therapy (without eltrombopag): HD-DXM ( DrugBank: Eltrombopag )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
63特発性血小板減少性紫斑病1

63. 特発性血小板減少性紫斑病


臨床試験数 : 391 薬物数 : 235 - (DrugBank : 50) / 標的遺伝子数 : 49 - 標的パスウェイ数 : 139
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04812483
(ClinicalTrials.gov)
September 1, 20221/3/2021Immunomodulation With Eltrombopag in ITPImmunomodulation in Young and Midlife Adults With Newly Diagnosed Primary Immune Thrombocytopenia (ITP): A Randomized Open Label Trial With High-dose Dexamethasone Versus Eltrombopag and High-dose DexamethasonePrimary Immune Thrombocytopenia (ITP)Drug: Eltrombopag (Revolade®);Drug: standard therapy (without eltrombopag): HD-DXMUniversity Children's Hospital BaselStiftung zur Förderung medizinischer und biologischer Forschung;Novartis Pharmaceuticals;University of Erlangen-Nürnberg, Department of BiologyRecruiting18 Years55 YearsAll24Phase 2Switzerland